Recently, some professionals have suggested a careful assessment of risk factors in relation to the amelioration of gastrointestinal motility disorders in patients: (1) underlying cardiac diseases, especially QT prolongation, (2) co-administration QT-prolonging agents or CYP3A4 inhibitors [46]. Here, CYP3A4 is linked to heart disorder.